ID

35340

Description

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02491398

Lien

https://clinicaltrials.gov/show/NCT02491398

Mots-clés

Versions (1)
  1. 28/02/2019 28/02/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

28 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Chronic Lymphocytic Leukemia NCT02491398

Anglais

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
Description

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Type de données

boolean

Alias
UMLS CUI [1]
C1302547
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
Description

Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment

Type de données

boolean

Alias
UMLS CUI [1,1]
C1328232
UMLS CUI [1,2]
C1708063
UMLS CUI [2,1]
C1328232
UMLS CUI [2,2]
C1710038
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
Description

Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0023434
UMLS CUI [2,2]
C0332121
UMLS CUI [3,1]
C1328232
UMLS CUI [3,2]
C0750729
UMLS CUI [3,3]
C1265611
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
Description

Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0023434
UMLS CUI [2]
C0002073
UMLS CUI [3]
C1268902
UMLS CUI [4]
C0003250
UMLS CUI [5,1]
C0003250
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C0686904
UMLS CUI [6,2]
C1710038
UMLS CUI [7,1]
C1328232
UMLS CUI [7,2]
C0750729
UMLS CUI [7,3]
C1265611
age ≥ 18 years old.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
signed written informed consent according to ich/eu/gcp and national local law.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received 2 or more lines of prior therapy.
Description

Prior Therapy Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
patients with:
Description

Patients Have

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C3539897
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
Description

Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C1142081
UMLS CUI [1,2]
C1332225
UMLS CUI [2]
C0349631
UMLS CUI [3]
C0019693
UMLS CUI [4,1]
C0019196
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0019163
UMLS CUI [5,2]
C0205318
UMLS CUI [6,1]
C0023890
UMLS CUI [6,2]
C0205318
Retour au début de la page

Similar models

Eligibility Chronic Lymphocytic Leukemia NCT02491398

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Item
diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008.
boolean
C1302547 (UMLS CUI [1])
Bendamustine/rituximab First line treatment | Bendamustine/rituximab Second line treatment
Item
patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group.
boolean
C1328232 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C1328232 (UMLS CUI [2,1])
C1710038 (UMLS CUI [2,2])
Prior Therapy Absent | Chronic Lymphocytic Leukemia Treatment required for | bendamustine/rituximab Course Quantity
Item
previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment.
boolean
C1514463 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0023434 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1328232 (UMLS CUI [3,1])
C0750729 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Prior Therapy Chronic Lymphocytic Leukemia | Alkylating Agents | Purine analog | Monoclonal Antibodies | Monoclonal Antibodies Absent | Patient need for Second line treatment | bendamustine/rituximab Course Quantity
Item
cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab.
boolean
C1514463 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C0002073 (UMLS CUI [2])
C1268902 (UMLS CUI [3])
C0003250 (UMLS CUI [4])
C0003250 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0686904 (UMLS CUI [6,1])
C1710038 (UMLS CUI [6,2])
C1328232 (UMLS CUI [7,1])
C0750729 (UMLS CUI [7,2])
C1265611 (UMLS CUI [7,3])
Age
Item
age ≥ 18 years old.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
signed written informed consent according to ich/eu/gcp and national local law.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy Quantity
Item
patients who have received 2 or more lines of prior therapy.
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Patients Have
Item
patients with:
boolean
C0030705 (UMLS CUI [1,1])
C3539897 (UMLS CUI [1,2])
Chronic lymphocytic leukaemia transformation Aggressive Lymphoma | Richter's syndrome | HIV Infection | Hepatitis C Uncontrolled | Hepatitis B Uncontrolled | Liver Cirrhosis Uncontrolled
Item
transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
boolean
C1142081 (UMLS CUI [1,1])
C1332225 (UMLS CUI [1,2])
C0349631 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
C0019196 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0019163 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0023890 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial